logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 5 of 5 Items
Showing 1 - 5 of 5 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M,  et al.
2025-02-01 • Lancet Global Health
2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article
|
Letter

Pregnancy outcomes in multidrug-resistant tuberculosis in TB-PRACTECAL

Crocker-Buque T, Lachenal N, Narasimooloo C, Abdrasuliev T, Parpieva N,  et al.
2024-08-15 • Clinical Infectious Diseases
2024-08-15 • Clinical Infectious Diseases
Journal Article
|
Research

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M,  et al.
2024-06-06 • Antimicrobial Agents and Chemotherapy
2024-06-06 • Antimicrobial Agents and Chemotherapy
Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...
Conference Material
|
Poster

ECG findings in BPaL-based TB treatment regimens: the geographical effect on QT prolongation

Motta I, Cusinato M, Ludman A, Abdrasuliev T, Butabekov I,  et al.
2023-06-07 • MSF Scientific Day International 2023
2023-06-07 • MSF Scientific Day International 2023
Journal Article
|
Research

Outcomes with a shorter multidrug-resistant tuberculosis regimen from Karakalpakstan, Uzbekistan

du Cros PAK, Khamraev AK, Tigay Z, Abdrasuliev T, Greig J,  et al.
2021-02-08 • ERJ open research
2021-02-08 • ERJ open research
BACKGROUND
In 2016, World Health Organization guidelines conditionally recommended standardised shorter 9–12-month regimens for multidrug-resistant (MDR) tuberculosis (TB) treatment....